Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXT-m200 in Methamphetamine Use Disorder
NCT05034874Phase 2Terminated
- Sponsor
- InterveXion Therapeutics
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in methamphetamine use disorder (MUD) comparing IXT-m200 with Placebo (2 arms). Primary endpoint: Percent of 20 Weeks Abstinent From Stimulants Following a 4-week Grace Period. Started Jun 2022; status: terminated.
02
Drugs
devextinetug
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT05034874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034874.